List of Next-Gen Sequencing Companies in South Korea - 4

3billion is revolutionizing the existing methods and procedures to enable more people to benefit from faster and much accurate diagnosis at an affordable cost. [Who is 3billion?] - 3billion provides an AI-driven clinical diagnostic testing on all 20,000+ genes encompassing 7,000+ rare genetic diseases for patients and physicians in need. - 3billion reanalyzes the undiagnosed patients’ genomic data every day without any additional charge. About 10% of undiagnosed patients can receive diagnosis by reanalysis. - More than 40,000 rare diseases patients from more than 60 countries have been tested. - More than 93% of acceptance rate on the 3billion’s test report by physicians. - 3billion has been collaborating with 100 medical institutions across 33 countries to make a diagnosis for rare disease patients. [Core Technology Features] - 3billion has expertise in medical genetics. We have streamlined the analysis pipeline using an automated variant prioritization system and are currently leading diagnostic technology by developing a pathogenicity prediction model of human variants. - 3billion devised a variant interpretation system, EVIDENCE, to automate the process. With the help of EVIDENCE, the variant interpretation takes less than 5 minutes per patient on average. - The EVIDENCE produces consistent variant interpretation according to the current medical guideline, ACMG-AMP interpretation guideline. 3billion's medical geneticist gives the diagnosis and confirms reported variants by Sanger validation (Richards S et al, 2015). - The analysis reflects the latest updates on diseases and genetic variants on daily basis. If any diagnosed case is identified through reanalysis, 3billion provides a report without any additional charge. - We offer Whole Exome Sequencing (WES) & Whole Genome Sequencing (WGS) for rare disease diagnosis. - Web-based portal service – easy access from all over the world. For any inquires, please contact us at support@3billion.io

Clinomics provides early diagnosis of cancer/diseases based on genome and pursues to overcome aging and diseases through liquid biopsy and Multi-Omics technology.COVID-19: EUA (02/2021)

NGeneBio Co., Ltd. is a leading company in molecular diagnostics (MDx) and companion diagnostics (CDx), which develops and provides next generation sequencing (NGS)-based in vitro diagnostics (IVD) panel and clinical analysis software (SW). NGeneBio was founded in October 2015, headquartered in Seoul, South Korea as a joint venture between Genecurix and Korea Telecom. The company launched NGS-based hereditary breast/ovarian cancer panel (BRCAaccuTestTM) with clinical analysis SW (NGeneAnalysisTM) in 2016. BRCA NGS panel for PARP inhibitor CDx test and solid tumor/hematologic cancer NGS panels will be launched, inclusive of clinical data analysis SW platform. The mission of the company is to provide clinically validated NGS based IVD/CDx products/services with convergence of innovative bioinformatics and SW development capacity for global market. For more information, visit www.ngenebio.com.

[About ROKIT Healthcare] ROKIT Healthcare is a First Mover in regenerative healthcare, pioneering innovations that reduce medical costs for governments and patients while driving healthcare transformation. Our mission is to extend healthy lifespans and enhance quality of life through cutting-edge technologies. At the heart of our vision lies the AI Hyper-Personalized Organ Regeneration Platform, a revolutionary solution designed to meet critical medical needs and redefine the future of medicine. [What We Do] - AI-Driven Organ Regeneration: Combining advanced bioprinting and AI to deliver hyper-personalized therapies for organ and tissue regeneration. - Anti-aging Bio-suppliment Products: Leading the anti-aging market with NMN, offering scientifically proven and effective solutions for better health. (ROKIT America) - Genomics: Utilizing AI-powered single-cell RNA-seq analysis to develop innovative diagnostics and precision medicine. (ROKIT Genomics) [Why ROKIT Healthcare?] We are committed to creating a sustainable and innovative healthcare ecosystem that benefits governments, healthcare providers, and patients. By addressing the root causes of medical challenges and reducing costs, we aim to make advanced healthcare accessible to all. [ROKIT Healthcare에 대하여] - ROKIT Healthcare는 재생 의료 분야의 First Mover로서, 정부와 환자의 의료비를 절감하고 의료 혁신을 주도하는 기술과 아이디어를 선도하고 있습니다. -우리의 사명은 최첨단 기술을 통해 건강 수명을 연장하고 삶의 질을 향상시키는 것입니다. 이러한 비전의 핵심에는 AI Hyper-Personalized Organ Regeneration Platform이 자리 잡고 있으며, 이는 의료의 중요한 과제를 해결하고 미래 의료의 패러다임을 재정의하는 혁신적인 솔루션입니다. [우리가 하는 일] - AI 기반 장기 재생: 첨단 바이오프린팅과 AI를 결합하여 개개인 맞춤형 장기 및 조직 재생 치료를 제공합니다. - 항노화 바이오 보충제 제품: 과학적으로 검증된 NMN으로 항노화 시장을 선도하며 건강을 위한 효과적인 솔루션을 제공합니다. (ROKIT America) - 유전체학: AI 기반 단일 세포 RNA-seq 분석을 활용하여 혁신적인 진단 및 정밀 의학 솔루션을 개발합니다. (ROKIT Genomics) [ROKIT Healthcare가 특별한 이유] 우리는 정부, 의료 제공자, 그리고 환자 모두에게 혜택을 주는 지속 가능하고 혁신적인 의료 생태계를 만들기 위해 노력하고 있습니다. 의료 문제의 근본적인 원인을 해결하고 비용을 절감함으로써, 선진 의료 기술을 모두가 접근 가능하게 만드는 것을 목표로 하고 있습니다.